EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1305	(514/312).CCLS.	USPAT; USOCR	OR	OFF	2006/08/03 10:36
L2	6291	quinolin	US-PGPUB; USPAT	OR	OFF	2006/08/03 10:35
L3	321	l1 and l2	US-PGPUB; USPAT	OR	OFF	2006/08/03 10:35
L4	135547	cancer	US-PGPUB; USPAT	OR	OFF	2006/08/03 10:36
L5	83	l4 and l3	US-PGPUB; USPAT	OR	OFF	2006/08/03 10:36
L6	1887	(514/312).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2006/08/03 10:37
L7	500	l6 and l2	US-PGPUB; USPAT	OR	OFF	2006/08/03 10:37
L8	169	l7 and l4	US-PGPUB; USPAT	OR	OFF	2006/08/03 10:37

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:517333 CAPLUS
DOCUMENT NUMBER: 141:207124
TITLE: Streamlined Processes for the Synthesis of a Farnesyl Transferase Inhibitor Drug Candidate
AUTHOR(S): Andresen, Brian M.; Couturier, Michel; Cronin, Brian; D'Occhio, Michael; Ewing, Marcus D.; Guinn, Mark; Hawkins, Joel M.; Jasys, V. John; LaGreca, Susan D.; Lyssikatos, Joseph P.; Moraski, Garrett; Ng, Karl; Raggon, Jeffrey W.; Stewart, A. Morgan; Tickner, Derek L.; Tucker, John L.; Urban, Frank J.; Vazquez, Enrique; Wei, Lulin
CORPORATE SOURCE: Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Organic Process Research & Development (2004), 8(4), 643-650
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:207124
IT 260050-75-7P 439153-65-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 6-[(4-chlorophenyl)hydroxy(3-methyl-3H-imidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one, a farnesyl transferase inhibitor drug candidate)
RN 260050-75-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 439153-65-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate, hydrate (2:2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



IT 439153-66-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 6-[(4-chlorophenyl)hydroxy(3-methyl-3H-imidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one, a farnesyl transferase inhibitor drug candidate)
RN 439153-66-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:777730 CAPLUS
DOCUMENT NUMBER: 137:299915
TITLE: Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition for the treatment of cancer
INVENTOR(S): Kajiji, Shama M.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078706	A1	20021010	WO 2002-US9751	20020329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002151563 A1 20021017 US 2002-103251 20020321
PRIORITY APPLN. INFO.: US 2001-279965P P 20010329
OTHER SOURCE(S): MARPAT 137:299915
IT 260050-75-7 260050-76-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition for the treatment of cancer)
RN 260050-75-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 260050-76-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:487550 CAPLUS
DOCUMENT NUMBER: 137:63258
TITLE: Crystal forms and production method of 6-[(4-chlorophenyl)(hydroxy)(3-methyl-3H-imidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one 2,3-dihydroxybutanedioate salts
INVENTOR(S): Li, Zheng Jane; Lyssikatos, Joseph Peter; Meltz, Clifford Nathaniel; Newton, Linda Sue; Tickner, Derek Lawrence
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050058	A1	20020627	WO 2001-IB2299	20011203
WO 2002050058	C1	20030220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432137	AA	20020627	CA 2001-2432137	20011203
AU 2002018436	A5	20020701	AU 2002-18436	20011203
BR 2001016302	A	20040113	BR 2001-16302	20011203
EP 1395577	A1	20040310	EP 2001-271105	20011203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004516287	T2	20040603	JP 2002-551554	20011203
US 2003032653	A1	20030213	US 2001-21201	20011207
US 6645982	B2	20031111		
US 2003212103	A1	20031113	US 2003-441567	20030520
US 6734308	B2	20040511		
US 2005020836	A1	20050127	US 2004-801471	20040315

PRIORITY APPLN. INFO.:

US 2000-256598P	P	20001219
WO 2001-IB2299	W	20011203
US 2001-21201	A3	20011207
US 2003-441567	A3	20030520

IT 439153-64-7P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(HPLC chiral resolution; crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl](ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)
RN 439153-64-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl- (9CI) (CA INDEX NAME)



IT 439153-67-0P 439153-68-1P 439153-69-2P
439153-70-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl](ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)

RN 439153-67-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-76-8
CMF C29 H22 Cl N3 O2

Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 439153-68-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 439153-64-7
CMF C29 H22 Cl N3 O2



CM 2

CRN 133-37-9
CMF C4 H6 O6

Relative stereochemistry.



RN 439153-69-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 439153-64-7
CMF C29 H22 Cl N3 O2



CM 2

CRN 133-37-9
CMF C4 H6 O6

Relative stereochemistry.



RN 439153-70-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 260050-76-8
CMF C29 H22 Cl N3 O2

Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 439153-65-8P 439153-66-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal structure; crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl]1(ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)

RN 439153-65-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate, hydrate (2:2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



RN 439153-66-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



IT 260050-75-7P 260050-76-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(separation of enantiomers; crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl]1(ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)
RN 260050-75-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-

yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 260050-76-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:161277 CAPLUS
DOCUMENT NUMBER: 132:194300
TITLE: Preparation of alkynyl-substituted quinolin-2-ones as anticancer agents
INVENTOR(S): La Greca, Susan Deborah; Lyssikatos, Joseph Peter
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

Published

WO 2000012499		A1	20000309	WO 1999-IB1398	19990806
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341690		AA	20000309	CA 1999-2341690	19990806
AU 9949254		A1	20000321	AU 1999-49254	19990806
BR 9913138		A	20010508	BR 1999-13138	19990806
EP 1107963		A1	20010620	EP 1999-933084	19990806
EP 1107963		B1	20060322		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200101343		T2	20010921	TR 2001-200101343	19990806
EE 200100118		A	20020617	EE 2001-118	19990806
JP 2002523504		T2	20020730	JP 2000-567527	19990806
JP 3495706		B2	20040209		
NZ 509372		A	20030829	NZ 1999-509372	19990806
AT 321037		E	20060415	AT 1999-933084	19990806
US 6150377		A	20001121	US 1999-383755	19990826
US 6294552		B1	20010925	US 2000-628039	20000727
ZA 2001001173		A	20020412	ZA 2001-1173	20010212
NO 2001000964		A	20010426	NO 2001-964	20010226
HR 2001000142		A1	20020228	HR 2001-142	20010227
BG 105365		A	20011130	BG 2001-105365	20010320
US 2002128287		A1	20020912	US 2001-900401	20010706
US 6579887		B2	20030617		

PRIORITY APPLN. INFO.:

US 1998-98145P	P	19980827
WO 1999-IB1398	W	19990806
US 1999-383755	A3	19990826
US 2000-628039	A3	20000727

OTHER SOURCE(S): MARPAT 132:194300

IT 260050-75-7P 260050-76-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of alkynyl-substituted quinolin-2-ones as anticancer agents)

RN 260050-75-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 260050-76-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT